Hyloris Pharmaceuticals S.A.
Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative pain, the opioid crisis, and acute pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the h… Read more
Hyloris Pharmaceuticals S.A. (0AB6) - Total Assets
Latest total assets as of June 2025: €37.05 Million EUR
Based on the latest financial reports, Hyloris Pharmaceuticals S.A. (0AB6) holds total assets worth €37.05 Million EUR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hyloris Pharmaceuticals S.A. - Total Assets Trend (2019–2024)
This chart illustrates how Hyloris Pharmaceuticals S.A.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Hyloris Pharmaceuticals S.A. - Asset Composition Analysis
Current Asset Composition (December 2024)
Hyloris Pharmaceuticals S.A.'s total assets of €37.05 Million consist of 71.9% current assets and 28.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 57.1% |
| Accounts Receivable | €4.86 Million | 11.8% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €3.84 Million | 9.3% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Hyloris Pharmaceuticals S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hyloris Pharmaceuticals S.A.'s current assets represent 71.9% of total assets in 2024, an increase from 62.5% in 2019.
- Cash Position: Cash and equivalents constituted 57.1% of total assets in 2024, up from 3.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, a decrease from 35.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 11.8% of total assets.
Hyloris Pharmaceuticals S.A. Competitors by Total Assets
Key competitors of Hyloris Pharmaceuticals S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
| No similar companies found. | ||
Hyloris Pharmaceuticals S.A. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Hyloris Pharmaceuticals S.A. generates 0.20x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Hyloris Pharmaceuticals S.A. is currently not profitable relative to its asset base.
Hyloris Pharmaceuticals S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.82 | 3.71 | 5.30 |
| Quick Ratio | 3.80 | 3.71 | 5.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €17.86 Million | € 23.94 Million | € 50.90 Million |
Hyloris Pharmaceuticals S.A. - Advanced Valuation Insights
This section examines the relationship between Hyloris Pharmaceuticals S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.35 |
| Latest Market Cap to Assets Ratio | 1.74 |
| Asset Growth Rate (YoY) | -13.3% |
| Total Assets | €41.34 Million |
| Market Capitalization | $71.96 Million USD |
Valuation Analysis
Above Book Valuation: The market values Hyloris Pharmaceuticals S.A.'s assets above their book value (1.74 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Hyloris Pharmaceuticals S.A.'s assets decreased by 13.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hyloris Pharmaceuticals S.A. (2019–2024)
The table below shows the annual total assets of Hyloris Pharmaceuticals S.A. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €41.34 Million | -13.31% |
| 2023-12-31 | €47.68 Million | -22.93% |
| 2022-12-31 | €61.86 Million | -2.49% |
| 2021-12-31 | €63.44 Million | -8.29% |
| 2020-12-31 | €69.18 Million | +1056.31% |
| 2019-12-31 | €5.98 Million | -- |